An experimental vaccine targeting one of the most common genetic drivers of pancreatic cancer has produced promising results in an early human trial, generating an immune response in 90% of high-risk participants.
The vaccine targets mutations in the KRAS gene, which are found in the majority of pancreatic cancers as well as in some early pancreatic lesions that can potentially develop into cancer.
How Does the Experimental Vaccine Work?
The vaccine, known as mKRAS-Vax, is being developed by researchers at Johns Hopkins University.
It is designed to train the immune system to recognize and attack cells carrying any of six KRAS mutations before those abnormal cells can potentially progress into cancer.
Researchers said the study represents an important early human trial demonstrating that a vaccine targeting KRAS mutations can safely generate durable immune responses.
20 High-Risk Participants Received Four Doses
The trial involved 20 participants considered to be at high genetic risk of developing pancreatic cancer who also had pancreatic abnormalities detected through imaging.
Each participant received four doses of the experimental vaccine over a period of 13 weeks.
Researchers then monitored their immune responses and health outcomes.
Immune Response Detected in 90% of Participants
The vaccine successfully stimulated immune cells capable of recognizing and remembering KRAS mutations in 18 of the 20 participants, representing 90% of the group.
Importantly, these immune cells remained detectable for as long as two years after vaccination, suggesting that the vaccine may be capable of producing a durable immune response.
No Pancreatic Cancer Cases During Follow-Up
After a median follow-up period of approximately 16.5 months, none of the participants had developed pancreatic cancer or a high-risk pancreatic lesion requiring surgical removal.
However, researchers emphasized that these findings do not prove that the vaccine can prevent pancreatic cancer.
The early-stage study was primarily designed to evaluate the vaccine’s safety and its ability to generate an immune response, rather than establish definitive cancer-prevention effectiveness.
What Side Effects Were Reported?
The experimental vaccine was generally well tolerated, with reported side effects ranging from mild to moderate.
The most common included:
- Injection-site reactions
- Fatigue
- Chills
- Flu-like symptoms
The preliminary findings therefore provided encouraging safety data while supporting further investigation of the vaccine.
Researchers Stress That This Is Only the Beginning
Study leader Dr. Elizabeth Jaffee of the Johns Hopkins Kimmel Cancer Center described the findings as an encouraging beginning but emphasized that considerably more research is required.
The results indicate that the immune system can be successfully stimulated against KRAS-mutated cells, but larger and longer clinical trials will be necessary to determine whether the approach can actually prevent pancreatic cancer.
Earlier Trial Paved the Way for Preventive Research
The current study builds on previous research involving a KRAS-targeting vaccine.
In 2020, researchers tested the approach in patients who had undergone surgery and remained at high risk of their pancreatic cancer returning.
Follow-up findings indicated that patients who developed strong immune responses following vaccination remained disease-free for extended periods, reaching at least five years in some cases.
Those encouraging findings helped motivate researchers to investigate whether the vaccine could be used even earlier — potentially before pancreatic cancer develops.
New Study Targets High-Risk Pancreatic Cysts
Researchers have also launched another study involving patients with high-risk pancreatic cysts who are undergoing surgery to have them removed.
The new research could allow scientists to examine more directly how vaccine-generated immune cells interact with pancreatic tissue that has the potential to become cancerous.
While the early findings offer a promising new direction for pancreatic cancer prevention research, the vaccine remains experimental. Larger clinical trials will be required before researchers can determine whether it can safely and effectively prevent the disease and eventually become part of routine medical care.
